Obesity Week 2023, which this yr might be performed simplest on web page in Dallas, Texas, from October 14 to 17, will as soon as once more be offering researchers and clinicians a big selection of the newest wisdom about weight problems — from preclinical analysis findings to the newest information about weight problems prevention and affected person control.
Almost 240 abstracts, that have been decided on by way of the assembly organizers and might be introduced as orals and posters, “encompass the latest advancements on a wide variety of topics, including anti-obesity medications, diagnosis and treatment of obesity, novel behavioral approaches, physical activity, aging, mechanisms and social determinants of obesity, bariatric surgical procedure and pediatric obesity,” Ursula White, PhD, chair of The Obesity Society (TOS) Programming Committee, stated in a press release that highlights 19 abstracts.
The assembly might be kicked off in a presidential plenary consultation with audio system that come with TOS president Elizabeth Parks, PhD, University of Missouri, in Columbia; the brand new editor of the magazine Obesity, Michael D. Jensen, MD, Mayo Clinic, Rochester, Minnesota; and TOS president-elect Jamy D. Ard, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Ard advised Medscape that he’ll be sharing plans of TOS to expand a requirements of care file for the remedy of adults with weight problems in collaboration with the Obesity Medicine Association, Obesity Canada, the American Society for Metabolic and Bariatric Surgery, the European Association for the Study of Obesity (EASO), and the International Federation for the Surgery of Obesity and Metabolic Disorders.
“We have excellent practices guidelines developed by a number of organizations,” Ard famous, “however the requirements of care will lend a hand to offer steerage to clinicians on the level of care and decision-making the place little proof might exist or the place pointers do not deal with this.
“With more options, increasing interest, and different types of clinicians engaging in treatment [of obesity], we need to have standards that identify what quality care looks like,” he wired.
This might be an ongoing procedure, Ard stated, beginning with figuring out subjects to deal with, then appearing medical critiques, after which publishing suggestions. The group expects to start out producing publications in 2024.
What’s New at Obesity Week 2023?
Asked what’s going to be of particular passion to clinicians on the present assembly, Ard stated, “There might be some late-breaking knowledge from the SURMOUNT-3 analysis program on tirzepatide. I’m certain that might be of top passion.
“I also believe there will be a few presentations that start to provide real-world experience with some of the latest generation of antiobesity medications,” he added.
The assembly will once more characteristic an Obesity Journal symposium that may spotlight 5 various, leading edge articles decided on by way of the editors and printed to coincide with the assembly.
One of the articles examines drivers of weight regain ― “behavioral, psychological, and environmental predictors of weight regain among successful weight losers in a weight management program” ― by way of Suzanne Phelan, PhD, and associates.
White, from the Pennington Biomedical Research Center, Baton Rouge, Louisiana, advised Medscape that as chair of the programming committee, she thinks that two symposia may additionally be of particular passion to clinicians:
-
A joint symposium by way of TOS, EASO, and the American Association of Clinical Endocrinology (AACE) on Sunday entitled, “Setting the Stage ― Clinical Outcomes to Guide Obesity Therapy,” will duvet how the severity of weight problems must be staged in a complication-centric means moderately than by way of weight or frame mass index (BMI), and reaction to remedy must be based upon medical results which can be correlated with weight loss. The AACE and EASO have followed the diagnostic time period, “adiposity-based chronic disease.”
-
The Blackburn Symposium on the use of BMI in weight problems prognosis and remedy might be performed on Monday and can deal with the historical past of BMI to diagnose and deal with weight problems, the professionals, cons, and implications of the use of BMI as a metric, and views on the use of BMI in the remedy of weight problems.
In a key lecture on Sunday, Lee Kaplan, MD, Harvard Medical School, and Ania Jastreboff, MD, PhD, Yale School of Medicine, will speak about what is in the pipeline for antiobesity drugs.
The assembly will come with posters and oral displays of a number of additional research of setmelanotide (advertised as IMCIVREE, Rhythm Pharmaceuticals), which is designed to revive customary starvation signaling alongside the MC4R pathway in the mind, which can also be impaired by way of genetic stipulations (POMC and LEPR deficiency, Bardet Biedl syndrome) or harm to the hypothalamus, normally from a mind tumor (hypothalamic weight problems).
These come with 12-month knowledge in hypothalamic weight problems (imply p.c BMI alternate from baseline used to be −24.9% throughout all sufferers, and −39.5% in youngsters [abstract]); 3-year knowledge in Bardet-Biedl syndrome (imply alternate in frame weight of greater than -20 kg [abstract]), and 4-year knowledge in POMC and LEPR deficiency (imply alternate in frame weight of greater than −30 kg [abstract]).
Other displays will come with a post hoc find out about of semaglutide for people who find themselves or don’t seem to be taking antidepressants, and a post hoc find out about of predictors of higher weight reduction with retatrutide, amongst others.
For extra diabetes and endocrinology news, practice us on X and Facebook.
[/gpt3]